Australia-based Telix Pharmaceuticals Inc. says it plans to add 20 executive-level and administrative positions to its U.S. headquarters in Fishers. The company, which manufactures radiopharmaceuticals used for medical imaging and the treatment of some cancers, established the facility in early 2020.
“We’re thrilled to be able to find a city that has the manufacturing infrastructure to support our operational expansion in the United States,” said Dr. Bernard Lambert, President Telix Americas. “We are excited for Telix’s future as we advance our pipeline of diagnostic and therapeutic products, and we will continue to implement our strategy that includes growing our team in the United States.”
The Indiana Economic Development Corp. offered Telix Pharmaceuticals up to $500,000 in conditional tax credits based on the company’s job creation plans.
“Telix had 49 other options to establish its U.S. headquarters, and we couldn’t be more grateful they chose Indiana to put down new roots,” said Jim Staton, IEDC senior vice president and chief business development officer. “We’re proud to have them join Indiana’s thriving life sciences sector and look forward to supporting their growth as they provide high-quality jobs for Hoosiers.”
Telix says it recently met with officials from the U.S. Food and Drug Administration regarding a New Drug Application for the company’s prostate cancer imaging investigational product Illuccix. Telix anticipates receiving FDA product approval by the end of 2021.